The vaccine is a new version of the single-dose Covid vaccine
China became the first country to approve an inhaled version of the vaccine Covid-19, made by Tianjin-based CanSino Biologics, pushed the company's shares as much as 14,5% higher on Monday morning in Hong Kong.
As Bloomberg reports, the relevant Chinese authority has approved CanSino's Ad5-nCoV for emergency use as a booster dose, the company said in a statement to the Hong Kong Stock Exchange on Sunday.
The vaccine is a new version of CanSino's single-dose Covid vaccine, the world's first to undergo human trials in March 2020 and which has been used in China, Mexico, Pakistan, Malaysia and Hungary since its launch in February 2021.
The inhaled version can stimulate cellular immunity to boost protection without intramuscular injection, CanSino said.